{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06362889",
            "orgStudyIdInfo": {
                "id": "HealMD-CBD-1"
            },
            "organization": {
                "fullName": "Rejuva Medical Aesthetics",
                "class": "OTHER"
            },
            "briefTitle": "Evaluating Microneedling With CBD and Hempseed Oil for Acne Vulgaris Safety and Efficacy",
            "officialTitle": "An Exploratory Study to Evaluate the Safety and Efficacy of Microneedling With Cannabidiol (CBD) and Hempseed Oil for Treating Acne Vulgaris",
            "therapeuticArea": [
                "Dermatology"
            ],
            "study": "evaluating-microneedling-with-cbd-and-hempseed-oil-for-acne-vulgaris-safety-and-efficacy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-05",
            "studyFirstSubmitQcDate": "2024-04-09",
            "studyFirstPostDateStruct": {
                "date": "2024-04-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Rejuva Medical Aesthetics",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "HealMD, LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "This is a prospective, single center, open label study to assess the safety and effectiveness of microneedling with CBD and hempseed oil for the treatment of moderate to severe acne in adults 22-years of age or older.The objective of this exploratory study is to evaluate the safety and efficacy of HealMD's CBD with hempseed oil to reduce the appearance of moderate to severe facial acne."
        },
        "conditionsModule": {
            "conditions": [
                "Acne Vulgaris (Disorder)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Microneedling with CBD oil",
                    "type": "EXPERIMENTAL",
                    "description": "All subjects will receive microneedling with CBD oil.At the baseline visit, the subject will undergo treatment by the principal investigator or subinvestigator. 3 days from the treatment visit, a phone call visit will be placed to assess any safety events and adherence to protocol guidelines. Day 21 visit, several assessments will be recorded and if no adverse events are reported related to the study device and/or procedure, a second treatment will be performed. After 3 days from the treatment visit, a phone call will be placed to assess any safety events. Subjects will have subjective assessments and photographs taken at all visits. At day 42, the subject will return for a third treatment if no adverse events related to the study device and/or procedure are reported. After 3 days from the treatment visit, a phone call will be placed to assess any safety events. On day 63,no treatment to be performed, only a safety assessment, standardized assessments/questionnaires and photography.",
                    "interventionNames": [
                        "Combination Product: Microneedling with CBD"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Microneedling with CBD",
                    "description": "Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil Organic Hemp Seed Oil- used as carrier oil for CBD isolate in Combination with Microneedling Device",
                    "armGroupLabels": [
                        "Microneedling with CBD oil"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Primary efficacy endpoints",
                    "description": "Reduction in the Global Acne Severity Scale (GAS) grade by Primary Investigator Reduction in the GAS grade by the Subject",
                    "timeFrame": "through study completion, approximately 70 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Secondary efficacy endpoints",
                    "description": "Improvement in the appearance of acne vulgaris papules and comedones in standardized photographs Monitoring for Adverse Events and Serious Adverse Events at all study visits",
                    "timeFrame": "through study completion, approximately 70 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or non-pregnant, non-lactating female, 22 years of age or older. Females of childbearing potential must agree to the use of a reliable method of contraception throughout the study.\n* Have a Global Acne Severity Scale Score of 3 (Moderate), 4 (Severe), or 5 (Very severe).\n* Have no plans to begin a new skincare routine or medical treatment program (Accutane) through the course of the study.\n* Willing to abstain from any aesthetic or surgical procedure in the treatment area for the duration of the study.\n\nExclusion Criteria:\n\n* Significant history or current evidence of any uncontrolled chronic or serious disease or medical condition that would, in the judgment of the investigator, would put the subject at undue risk or compromise the study assessments.\n* Employees of the Investigator or research center or their immediate family members.\n* Inability to understand the requirements of the study and the relative information and are unable or not willing to comply with the study protocol.\n* The use of Accutane (Isotretinoin) within 6-months.\n* The use of topical or oral therapies that include benzoyl peroxide, azelaic acid, salicylic acid, and hydroquinone 30 days prior to study entry.\n* Exposure to any other investigational drug/device within 30 days prior to study entry.\n* Sunburned at time of anticipated treatment. Subject must also be willing to avoid significant sun exposure throughout participation\n* Recent facial plastic surgery, aesthetic treatment, or dermatological treatment at treatment sites that would interfere with ability to receive microneedling.\n* Facial hair that would interfere with the visualization of treatment sites.\n* Subject with abnormal vision assessments.\n* Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g. due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "22 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "LaRyel Waldon, BS",
                    "role": "CONTACT",
                    "phone": "4246442400",
                    "email": "laryel@rejuvamedical.org"
                },
                {
                    "name": "Brian McDonnell, BS",
                    "role": "CONTACT",
                    "phone": "9492996747",
                    "email": "mcdonnellbrian7@gmail.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kian Karimi, MD",
                    "affiliation": "Rejuva Medical Aesthetics",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Rejuva Medical Aesthetics",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90025",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "LaRyel A Waldon, B.S.",
                            "role": "CONTACT",
                            "phone": "424-644-2400",
                            "email": "laryel@rejuvamedical.org"
                        },
                        {
                            "name": "Margaux Oldfield",
                            "role": "CONTACT",
                            "phone": "4246442400",
                            "email": "margaux@rejuvamedical.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "33469147",
                    "type": "BACKGROUND",
                    "citation": "Blaskovich MAT, Kavanagh AM, Elliott AG, Zhang B, Ramu S, Amado M, Lowe GJ, Hinton AO, Pham DMT, Zuegg J, Beare N, Quach D, Sharp MD, Pogliano J, Rogers AP, Lyras D, Tan L, West NP, Crawford DW, Peterson ML, Callahan M, Thurn M. The antimicrobial potential of cannabidiol. Commun Biol. 2021 Jan 19;4(1):7. doi: 10.1038/s42003-020-01530-y."
                },
                {
                    "pmid": "35535052",
                    "type": "BACKGROUND",
                    "citation": "Peyravian N, Deo S, Daunert S, Jimenez JJ. The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne. J Inflamm Res. 2022 May 3;15:2795-2801. doi: 10.2147/JIR.S355489. eCollection 2022."
                },
                {
                    "pmid": "31881765",
                    "type": "BACKGROUND",
                    "citation": "Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants (Basel). 2019 Dec 25;9(1):21. doi: 10.3390/antiox9010021."
                },
                {
                    "pmid": "33168643",
                    "type": "BACKGROUND",
                    "citation": "Nachnani R, Raup-Konsavage WM, Vrana KE. The Pharmacological Case for Cannabigerol. J Pharmacol Exp Ther. 2021 Feb;376(2):204-212. doi: 10.1124/jpet.120.000340. Epub 2020 Nov 9."
                },
                {
                    "pmid": "30697147",
                    "type": "BACKGROUND",
                    "citation": "Muller C, Morales P, Reggio PH. Cannabinoid Ligands Targeting TRP Channels. Front Mol Neurosci. 2019 Jan 15;11:487. doi: 10.3389/fnmol.2018.00487. eCollection 2018."
                },
                {
                    "pmid": "33629929",
                    "type": "BACKGROUND",
                    "citation": "Huang T, Xu T, Wang Y, Zhou Y, Yu D, Wang Z, He L, Chen Z, Zhang Y, Davidson D, Dai Y, Hang C, Liu X, Yan C. Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. Autophagy. 2021 Nov;17(11):3592-3606. doi: 10.1080/15548627.2021.1885203. Epub 2021 Feb 25."
                },
                {
                    "pmid": "25061872",
                    "type": "BACKGROUND",
                    "citation": "Olah A, Toth BI, Borbiro I, Sugawara K, Szollosi AG, Czifra G, Pal B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, Biro T. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014 Sep;124(9):3713-24. doi: 10.1172/JCI64628. Epub 2014 Jul 25."
                },
                {
                    "pmid": "37799356",
                    "type": "BACKGROUND",
                    "citation": "Alqam ML, Jones BC, Hitchcock TM. Study to determine the safety and efficacy of microneedling as an effective treatment for acne vulgaris. Skin Health Dis. 2023 Jul 5;3(5):e264. doi: 10.1002/ski2.264. eCollection 2023 Oct."
                },
                {
                    "pmid": "33998871",
                    "type": "BACKGROUND",
                    "citation": "Land MH, Toth ML, MacNair L, Vanapalli SA, Lefever TW, Peters EN, Bonn-Miller MO. Effect of Cannabidiol on the Long-Term Toxicity and Lifespan in the Preclinical Model Caenorhabditis elegans. Cannabis Cannabinoid Res. 2021 Dec;6(6):522-527. doi: 10.1089/can.2020.0103. Epub 2020 Nov 20."
                },
                {
                    "pmid": "32597140",
                    "type": "BACKGROUND",
                    "citation": "Cerne K. Toxicological properties of Delta9-tetrahydrocannabinol and cannabidiol. Arh Hig Rada Toksikol. 2020 Mar 1;71(1):1-11. doi: 10.2478/aiht-2020-71-3301."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "All IPD that underlie results in a publication will be made available.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "The Data will be made available within 6 months of the study's conclusion, and will remain available for at least 5 years.",
            "accessCriteria": "Signing a data use agreement."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000152",
                    "term": "Acne Vulgaris"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017486",
                    "term": "Acneiform Eruptions"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000012625",
                    "term": "Sebaceous Gland Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3512",
                    "name": "Acne Vulgaris",
                    "asFound": "Acne Vulgaris",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8219",
                    "name": "Exanthema",
                    "relevance": "LOW"
                },
                {
                    "id": "M19751",
                    "name": "Acneiform Eruptions",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15439",
                    "name": "Sebaceous Gland Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M5445",
                    "name": "Cannabidiol",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AntiConv",
                    "name": "Anticonvulsants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}